Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Novacyt

Market Cap 28.95M 33.2M 26.81M 25.1M 47.07M 3.13B 47.36M 318M 123M 1.54B 125M 122M 5.35B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 30.9M 35.44M 28.62M 26.79M 50.25M 3.34B 50.55M 340M 132M 1.65B 133M 130M 5.72B EV / Sales 2026 *
1.01x
EV / Sales 2027 * 0.97x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-5.90%
6 months-5.90%
Current year-5.90%
Current year 0.48
Extreme 0.48
0.48
1 year 0.48
Extreme 0.48
0.55
3 years 0.48
Extreme 0.48
1.25
5 years 0.48
Extreme 0.48
5.77
10 years 0
Extreme 0
16
Manager TitleAgeSince
Chief Executive Officer 53 2024-04-30
Director of Finance/CFO 44 2019-12-31
Chief Operating Officer - 2021-10-31
Director TitleAgeSince
Director/Board Member 75 2006-07-02
Director/Board Member 60 2017-06-26
Director/Board Member 44 2024-01-01
Change 5-day change 1-year change 3-year change Capi.($)
-5.90%-.--% - - 33.2M
+0.41%+0.14%-37.96%-42.15% 547M
-4.08%-23.95%+187.15% - 431M
-0.28%-7.91%-36.10%+14.12% 132M
+3.66%+9.32%+65.05%+115.19% 129M
Average -1.24%-6.82%+44.53%+29.05% 309.73M
Weighted average by Cap. -1.02%-8.18%+51.33%-7.78%

Financials

2026 *2027 *
Net sales 30.52M 35.01M 28.27M 26.47M 49.63M 3.3B 49.93M 335M 130M 1.63B 131M 129M 5.65B 34.86M 39.98M 32.29M 30.22M 56.68M 3.77B 57.03M 383M 148M 1.86B 150M 147M 6.45B
Net income - -
Net Debt 1.96M 2.24M 1.81M 1.7M 3.18M 212M 3.2M 21.49M 8.33M 104M 8.42M 8.24M 362M 4.84M 5.55M 4.48M 4.2M 7.87M 524M 7.92M 53.2M 20.62M 258M 20.85M 20.4M 896M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216

Annual profits - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!